Overview
Ryan Sugarman is an Oncologist and a Hematologist in New York, New York. Dr. Sugarman is rated as an Experienced provider by MediFind in the treatment of Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency. His top areas of expertise are Stomach Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Colorectal Cancer.
His clinical research consists of co-authoring 15 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- OTHER MEDICARE PART D
- HMO
- POS
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- INSURANCE PLAN
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- OTHER COMMERCIAL
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
1275 York Ave, New York, NY 10065
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
WPHPA Cancer And Blood Specialists Of New York
Dr. Lederman received her medical degree from Cornell Medical College and completed residency in Internal Medicine at The Mount Sinai Hospital in New York. After serving one year as Chief Resident in Internal Medicine at Elmhurst Hospital in Queens, she completed fellowship training in Hematology and Oncology at New York Medical College/Westchester Medical Center. She served New York Medical College as Assistant Clinical Professor for several years, as well as being an active member of the New York Blood Center Transfusion Service. Dr. Lederman is rated as a Distinguished provider by MediFind in the treatment of Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency. Her top areas of expertise are GTP Cyclohydrolase 1 Deficiency, Pseudocholinesterase Deficiency, Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency, and Deep Vein Thrombosis.
New York University
Marc Braunstein is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Braunstein is rated as a Distinguished provider by MediFind in the treatment of Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency. His top areas of expertise are Multiple Myeloma, Schnitzler Syndrome, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration.
WPHPA Cancer And Blood Specialists Of New York
Dr. Dan Costin is Director of the White Plains Hospital Center for Cancer Care. He has been practicing medical oncology and hematology in Westchester since 1993. He received his B.S. in biochemistry at the University of California in Los Angeles and his medical degree at the University of California in San Francisco. He completed his internal medicine residency at Beth Israel Hospital in Boston in 1990, his fellowship in medical oncology at the National Cancer Institute in Bethesda in 1991, and his fellowship in hematology at New York University in 1993. He has been an attending physician at White Plains Hospital since 1993 and served as section chief of the department of Hematology-Oncology from 1999 to 2007. Dr. Costin is rated as a Distinguished provider by MediFind in the treatment of Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency. His top areas of expertise are Paget Disease of the Breast, Chondrosarcoma, Osteosarcoma, and Angiosarcoma.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Colorectal CancerDr. Sugarman isDistinguished. Learn about Colorectal Cancer.
- Familial Colorectal CancerDr. Sugarman isDistinguished. Learn about Familial Colorectal Cancer.
- Familial Pancreatic CancerDr. Sugarman isDistinguished. Learn about Familial Pancreatic Cancer.
- Gastroesophageal Junction CancerDr. Sugarman isDistinguished. Learn about Gastroesophageal Junction Cancer.
- Pancreatic CancerDr. Sugarman isDistinguished. Learn about Pancreatic Cancer.
- Stomach CancerDr. Sugarman isDistinguished. Learn about Stomach Cancer.
- Advanced
- Anal CancerDr. Sugarman isAdvanced. Learn about Anal Cancer.
- Appendix CancerDr. Sugarman isAdvanced. Learn about Appendix Cancer.
- Cholangiocarcinoma (Bile Duct Cancer)Dr. Sugarman isAdvanced. Learn about Cholangiocarcinoma (Bile Duct Cancer).
- Gallbladder AdenocarcinomaDr. Sugarman isAdvanced. Learn about Gallbladder Adenocarcinoma.
- Gallbladder CancerDr. Sugarman isAdvanced. Learn about Gallbladder Cancer.
- Lynch SyndromeDr. Sugarman isAdvanced. Learn about Lynch Syndrome.
- Experienced
- Ampullary CancerDr. Sugarman isExperienced. Learn about Ampullary Cancer.
- Esophageal CancerDr. Sugarman isExperienced. Learn about Esophageal Cancer.
- Fibrolamellar CarcinomaDr. Sugarman isExperienced. Learn about Fibrolamellar Carcinoma.
- Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
- Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
- GTP Cyclohydrolase 1 DeficiencyDr. Sugarman isExperienced. Learn about GTP Cyclohydrolase 1 Deficiency.